Repotrectinib for treating advanced or metastatic nonsmall-cell lung cancer with ROS1-postive mutation

Repotrectinib is currently in clinical development for treating advanced or metastatic non-smallcell lung cancer (NSCLC) with ROS1-positive mutation. NSCLC is the most common type of lung cancer. Metastatic and advanced cancer means that the cancer has spread and curative treatment with surgery is unsuitable. A ROS1-positive lung cancer refers to any lung cancer that tests positive for a mutation in the ROS1 gene. ROS1-positive lung cancer tends to be aggressive and can spread to the brain and the bones which can lead to increased mortality. Current treatment options tend to cause acquired resistant mutations which make the treatment of ROS1-positive lung cancers more challenging.